Xconomy | Seattle - Business + Technology in the Exponential Economy

Biotech, Hepatitis C, clinical trials

Zymo Drug Kills Hep C Virus

Luke Timmerman 4/24/09

ZymoGenetics (NASDAQ: ZGEN), a Seattle biotech company, and partner Bristol-Myers Squibb said today that a drug they are co-developing for hepatitis C was able to kill the virus with minimal side effects in a small four-week study. The trial looked at pegylated interferon lambda on its own, or in combination with a standard ribavirin treatment. The full data was presented at the European Association for the Study of the Liver meeting in Copenhagen, Denmark.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments (5) | Reprints | Share:

Reader Comments

deborah anderson
5/13/09 10:55 pm

help me
larry yarbrough
7/5/09 5:24 pm

I do hope this treatment works and it’s on the market soon. The side effects
of current treatment of pegintron nearly killed my wife.
Ray Patterson
11/12/09 1:45 am

Please help me. I could not complete the standard treatment because of the nasty side effects. It almost killed me. I will volunteer to be a test subject for this promising new drug. Please help.

Ray Patterson
rptexas@gmail.com
Luke Timmerman
11/12/09 10:38 am

Ray—you can find more information about an ongoing clinical trial of the ZymoGenetics drug at this link below.

http://clinicaltrials.gov/ct2/show/NCT01001754?term=IL-29&rank=2